← Back to guidelines
Infectious Disease39 papers

Viral hepatitis D

Last edited: 4/10/2026

Overview

Hepatitis D virus (HDV) is a hepatotropic virus that requires hepatitis B virus (HBV) for replication and infectivity 2. It significantly impacts global health, with varying prevalence across regions 2.

Diagnosis

Management

  • Pegylated interferon-alfa-2a (PEG-IFNa) 180 μg weekly in combination with tenofovir disoproxil fumarate (TDF) 300 mg once daily was investigated for hepatitis D treatment 1.
  • Hepatitis flares, defined as ALT increases above 10 times the upper limit of normal or increases of more than 2.5-fold above baseline or nadir values, occurred in 23% of patients during treatment and 11.7% post-treatment in one study 1.
  • ALT flares did not differ between PEG-IFNa plus placebo and PEG-IFNa plus TDF arms 1.
  • ALT flares did not differ between cirrhotic and non-cirrhotic patients, and no liver decompensation occurred in cirrhotic patients during or after a flare 1.
  • Fifty-four percent of patients experiencing an ALT flare had a decrease in HDV RNA (>1 log10 copies/mL) 1.
  • Premature withdrawal from PEG-IFNa therapy due to ALT flares is not indicated 1.
  • Special Populations

    Key Recommendations

  • Pegylated interferon-alfa-2a therapy in patients with hepatitis D may lead to ALT flares in over one-third of cases, but these flares do not appear to pose a significant safety risk and should not prompt treatment withdrawal 1. (Evidence: Moderate)
  • Global prevalence of HDV varies by region, with MENA and Africa showing notable rates 2. (Evidence: Moderate)
  • Tailored public health strategies, including vaccination and awareness campaigns, are needed to address the diverse global prevalence patterns of hepatotropic viruses 2. (Evidence: Moderate)
  • References

    1 Hardtke S, Yurdaydin C, Caruntu FA, Curescu MG, Yalcin K, Akarca US et al.. Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection. Journal of viral hepatitis 2025. link 2 Adeiza S, Islam M, Mungadi H, Shuaibu A, Sah R. A preregistered meta-meta-analysis on the global distribution of Hepatotropic Viruses. Voprosy virusologii 2024. link

    Original source

    1. [1]
      Frequency, Severity and Impact of Pegylated Interferon Alpha-Associated Flares in Hepatitis D Infection.Hardtke S, Yurdaydin C, Caruntu FA, Curescu MG, Yalcin K, Akarca US et al. Journal of viral hepatitis (2025)
    2. [2]
      A preregistered meta-meta-analysis on the global distribution of Hepatotropic Viruses.Adeiza S, Islam M, Mungadi H, Shuaibu A, Sah R Voprosy virusologii (2024)
    3. [3]
      HEP DART 2003: Frontiers in drug development for viral hepatitis.Raney AK, Hamatake RK, Hong Z Expert opinion on investigational drugs (2004)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG